mitoxantrone and Cancer of Ovary studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

Excerpt	Relevance	Reference
"In June 1986 we initiated an intra-peritoneal (IP) mitoxantrone chemotherapy trial as consolidation treatment for ovarian carcinoma in CR or PR after induction therapy (surgery + CHAP combination chemotherapy)."	9.07	Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Dufour, P; Herbrecht, R; Maloisel, F; Renaud, R; Ritter, P; Wendling, C, 1991)
" Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present."	7.69	Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994)
"Between 1992-97, 5 patients (breast cancer-4 pts, ovarian cancer-1 pt) were admitted to the University Hospital of Tromsø due to a life-threatening MPE."	6.69	Mitoxantrone in malignant pericardial effusion. ( Aasebø, U; Himmelmann, A; Lunde, P; Norum, J, 1998)
"Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD."	6.68	A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997)
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."	6.67	Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"In June 1986 we initiated an intra-peritoneal (IP) mitoxantrone chemotherapy trial as consolidation treatment for ovarian carcinoma in CR or PR after induction therapy (surgery + CHAP combination chemotherapy)."	5.07	Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Dufour, P; Herbrecht, R; Maloisel, F; Renaud, R; Ritter, P; Wendling, C, 1991)
"In a non-randomized clinical trial, combined intraperitoneal therapy with recombinant interferon alpha-2b (20-50 MU) and mitoxantrone (20-50 mg) was studied for recurrent ovarian cancer with ascites."	5.07	Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. ( Gröhn, P; Kivinen, S; Mäenpää, J; Räisänen, I; Sipilä, P; Väyrynen, M, 1994)
"A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies."	5.05	[Phase II study of mitoxantrone]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Okada, Y; Tada, A; Usui, N, 1984)
" The pericardial effusion recurred and was then successfully treated with intrapericardial mitoxantrone."	3.74	Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report. ( Brown, JV; Epstein, HD; Goldstein, BH; Micha, JP; Rettenmaier, MA; Zusman, D, 2007)
" Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present."	3.69	Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994)
"35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)."	3.68	[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991)
"To define both the toxicity and efficacy of intraperitoneal mitoxantrone in the treatment of refractory ovarian carcinoma, 31 patients were entered onto a phase II trial of this agent delivered in a 2 L treatment volume on a monthly basis."	3.68	Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. ( Almadrones, L; George, M; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S, 1990)
"In this series confined to patients with minimal residual disease after initial therapy subjected to second-line intraperitoneal treatment, it appears to identify a poor prognostic (positive) subset for survival."	2.70	Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. ( Alberts, DS; Belt, RJ; Cote, R; Felix, J; Hawes, D; Liu, PY; Muggia, FM; Terada, K; Wilczynski, S, 2002)
"The management of ovarian cancer in the aged patient is many-sided: the diagnosis can be difficult and delayed, and aggressive surgery is often not attempted because of concomitant morbidity."	2.70	Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. ( Amichetti, M; Artioli, G; Azzoni, P; Donach, M; Endrizzi, L; Ferrazzi, E; Monfardini, S; Nicoletto, MO; Prosperi, A; Salvagno, L; Sileni, VC; Talamini, R; Tumolo, S; Veronesi, A; Visonà, E, 2001)
" Maximal mitoxantrone plasma concentrations (Cmax), times to Cmax (Tpeak) and area under the curves (AUC) were highly variable between subjects (Cmax 14-337 ng/ml; Tpeak 0."	2.69	Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. ( Cartei, G; Corsini, A; De Paoli, M; Ferrazzi, E; Galeotti, F; Nicoletto, MO; Padrini, R; Palumbo, M; Riddi, F, 2000)
"In the human clonogenic assay, mitoxantrone possesses among the steepest dose-response curves of any cytotoxic agent against ovarian cancer."	2.69	Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. ( Belinson, J; Ernst, S; Homesley, H; Kennedy, A; Lichtman, SM; Markman, M; Omura, G; Webster, K, 1998)
"Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (i."	2.69	Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. ( Aydmer, A; Bengisu, E; Berkman, S; Saip, P; Salihoğlu, Y; Topuz, E, 1998)
"Between 1992-97, 5 patients (breast cancer-4 pts, ovarian cancer-1 pt) were admitted to the University Hospital of Tromsø due to a life-threatening MPE."	2.69	Mitoxantrone in malignant pericardial effusion. ( Aasebø, U; Himmelmann, A; Lunde, P; Norum, J, 1998)
"Mitoxantrone was infused continuously in 21-day courses beginning every 6 weeks."	2.68	Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. ( Aversa, S; Azzoni, P; Endrizzi, L; Fiorentino, MV; Koussis, H; Nicoletto, MO; Padrini, R; Palumbo, M; Rosabian, A, 1995)
"Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD."	2.68	A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997)
"In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity."	2.68	Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. ( Bonazzi, C; Colombo, N; Maneo, A; Mangioni, C; Marzola, M; Parma, G; Pittelli, MR, 1996)
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."	2.67	Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"treatment with mitoxantrone had AUCs and plasma peak levels of the drug that were significantly higher than those in non-responders (P = 0."	2.67	Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. ( Costa, L; Ferrazzi, E; Monfardini, S; Nascimben, O; Nicoletto, MO; Padrini, R; Palumbo, M; Tumolo, S; Vinante, O; Visonà, E, 1993)
"All six of the assessable patients with ovarian cancer responded: CR in five (83%) and partial remission (PR) in one (17%); the CRs have lasted 7 to 30+ months."	2.67	Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. ( Alberts, DS; Dolan, JR; McCloskey, T; McKenzie, RS; Rad, N; Sosman, JA; Stiff, PJ, 1994)
"Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies."	2.67	Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994)
"Ovarian cancer is the seventh most common cancer among women worldwide, causing approximately 120,000 deaths every year."	1.46	The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells. ( Ferreira, A; Gabler, F; Oróstica, L; Romero, CA; Selman, A; Vega, M; Vera, CA, 2017)
"Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours."	1.42	Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015)
"Mitoxantrone was incorporated into the folate-conjugated albumin nanoparticles, and the final nanoparticle size was 68 nm, as measured by a laser light scattering particle analyzer."	1.36	Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles. ( Hou, SX; Hu, WJ; Wang, CY; Zhang, JQ; Zhang, LK, 2010)
"We selected breast, ovarian and colon cancer cells (MCF-7, IGROV-1 and S-1) after exposure to 14 or 21 nM doxorubicin for only 10 days."	1.35	Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. ( Ambudkar, SV; Bates, SE; Calcagno, AM; Caplen, NJ; Chewning, KJ; Fostel, JM; Martin, SE; Salcido, CD; To, KK; Varticovski, L; Wu, CP, 2008)
"05) in mice dosed with WK-X-34 (20 mg/kg i."	1.33	In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. ( Breitbach, K; Jekerle, V; Klinkhammer, W; Piquette-Miller, M; Reilly, RM; Scollard, DA; Wiese, M, 2006)
"We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began."	1.31	Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. ( Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y, 2000)
"Patients with stage I ovarian cancer show a high incidence of recurrent disease ranging from 30% to 50%, which may be associated with a shortened survival."	1.31	The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma. ( Aydiner, A; Bengisu, E; Berkman, S; Eralp, Y; Saip, P; Saliho, Y; Salihoğlu, Y; Taş, F; Topuz, E, 2001)
"Forty-one ovarian cancer patients with less than 2 cm residual disease after systemic cisplatin-based chemotherapy received 4 courses of an ip regimen including cisplatin (75 mg/m2), mitoxantrone (20 mg/m2), and interferon-alpha 2b (30 mil IU/m2)."	1.29	Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. ( Cardone, A; Conforti, S; Facchini, G; Frasci, G; Iaffaioli, RV; Mastrantonio, P; Persico, G; Tortoriello, A, 1993)
"A2780 human ovarian cancer cell line and its multidrug resistant counterpart A2780-DX3 were utilized for this in vitro study."	1.29	Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. ( Cimoli, G; Conte, P; De Sessa, F; Mazzoni, A; Parodi, S; Russo, P; Valenti, M, 1993)
"TNF endogenously secreted by human ovarian cancer cell lines is very efficient in potentiating the activity of DNA topoisomerase II inhibitors (doxorubicin, mitoxantrone, VP16)."	1.29	Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. ( Clerico, L; Debernardis, D; Mancuso, T; Ottoboni, C; Parodi, S; Russo, P; Stanzione, S, 1996)
"Human ovarian cancer cells A2780, selected for resistance to doxorubicin (A2780-DX3), are cross-resistant to various other topoisomerase-II-targeted drugs but not to vinblastine."	1.29	"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). ( Cimoli, G; De Sessa, F; Mazzoni, A; Noviello, E; Parodi, S; Rovini, E; Russo, P; Valenti, M, 1995)
" The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing."	1.29	Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. ( Alberts, D; Barakat, R; Brodar, F; Curtin, J; Hakes, T; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S, 1993)
"treatment with mitoxantrone."	1.28	Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ( Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992)
"Eight human ovarian cancer lines grown in nude mice were used to compare the activity of doxorubicin, epirubicin, mitoxantrone and menogaril."	1.28	Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. ( Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM, 1990)
"Pleural effusions are a frequent complication of malignant gynecologic diseases, especially in breast cancer with an incidence of about 50%."	1.28	[Local treatment of malignant pleural effusion in gynecologic tumors]. ( Kuhn, W; Musch, E; Seitzer, D, 1990)
"Thirty-six patients with epithelial ovarian cancer, incompletely resected at primary laparotomy, were treated with one of two intensive cis-platinum-based combination chemotherapy regimens."	1.28	Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. ( Blackledge, G; Chan, KK; Lawton, FG; Luesley, DM; Redman, CW, 1989)
"Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks."	1.27	Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. ( Asbury, R; Bundy, B; Ehrlich, CE; Graham, J; Muss, HB, 1984)
"Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients."	1.27	Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. ( Alberts, DS; Graham, V; McCloskey, T; McDonald, L; Peng, YM; Rivest, R; Roe, D; Surwit, EA, 1988)
" We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i."	1.27	Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, P; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1987)
" We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i."	1.27	Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, B; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1988)
" Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule."	1.27	Pharmacology of mitoxantrone: mode of action and pharmacokinetics. ( Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985)

Timeframe	Studies, this research(%)	All Research%
pre-1990	16 (16.67)	18.7374
1990's	57 (59.38)	18.2507
2000's	20 (20.83)	29.6817
2010's	3 (3.13)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma[NCT00002474]	Phase 2	0 participants	Interventional	1991-02-28	Completed
Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501]	Phase 1	3 participants (Actual)	Interventional	2009-04-30	Terminated (stopped due to choice of the principal investigator)
Role of PET/CT in Peritoneal Deposits Assessment[NCT06137417]		50 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecologic oncology, 2002, Volume: 87, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials	2002
Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecologic oncology, 2004, Volume: 94, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophospha	2004
[Phase II study of mitoxantrone]. Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8 Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human	1984
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. British journal of cancer, 1994, Volume: 69, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Granulocyte Colony-S	1994
Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies. Bone marrow transplantation, 1995, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Trans	1995
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecologic oncology, 1995, Volume: 57, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cyc	1995
Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:6 Topics: Adult; Aged; CA-125 Antigen; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Cystade	1995
An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer. Tumori, 1994, Dec-31, Volume: 80, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Fema	1994
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:4 Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito	1994
Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. Annales chirurgiae et gynaecologiae. Supplementum, 1994, Volume: 208 Topics: Adult; Aged; Ascites; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administrati	1994
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer, 1994, Apr-01, Volume: 73, Issue:7 Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc	1994
Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta	1994
Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Infusions, Parenteral; Middle Aged; Mitoxantrone; Ov	1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment. Gynecologic oncology, 1993, Volume: 49, Issue:2 Topics: Adult; Aged; Female; Humans; Injections, Intraperitoneal; Middle Aged; Mitoxantrone; Ovarian Neoplas	1993
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. Gynecologic oncology, 1996, Volume: 61, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female	1996
A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	1996
An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:13-14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Female; Humans; Ifosfa	1995
Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Evaluation Studies as Topic	1996
Intraperitoneal cisplatin--mitoxantrone in ovarian cancer patients with minimal residual disease. European journal of gynaecological oncology, 1997, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged;	1997
A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Bone marrow transplantation, 1997, Volume: 20, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carbo	1997
Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. European journal of gynaecological oncology, 1998, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Feasibility Studi	1998
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. Gynecologic oncology, 1998, Volume: 70, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Administration Schedule;	1998
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone	1997
Mitoxantrone in malignant pericardial effusion. Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged	1998
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecologic oncology, 1999, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disea	1999
Peritoneal carcinomatosis from ovarian cancer: cytoreductive surgery and intraperitoneal chemotherapy. Journal of chemotherapy (Florence, Italy), 1999, Volume: 11, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female	1999
Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Female; Hot Temperature; Humans; Infusions, Parenteral; Middle A	2000
Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. Journal of surgical oncology, 2000, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Femal	2000
Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. Gynecologic oncology, 2001, Volume: 80, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administr	2001
Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecologic oncology, 2001, Volume: 83, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Epiru	2001
Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feasibility Studies; Female;	1991
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:6 Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Injec	1991
Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. Bulletin du cancer, 1991, Volume: 78, Issue:3 Topics: Adult; Aged; Carcinoma; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Middle Aged;	1991

Article	Year
1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. Journal of medicinal chemistry, 1998, Aug-13, Volume: 41, Issue:17 Topics: Anthraquinones; Antineoplastic Agents; Cell Division; Cell Survival; Doxorubicin; Enzyme Inhibitors;	1998
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc	2015
The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells. International journal of oncology, 2017, Volume: 50, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Calreticulin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cel	2017
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecologic oncology, 2009, Volume: 113, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallo	2009
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay and drug development technologies, 2009, Volume: 7, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; C	2009
Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles. Archives of pharmacal research, 2010, Volume: 33, Issue:8 Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fema	2010
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer research, 2005, Aug-01, Volume: 65, Issue:15 Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Ne	2005
[Tumor cell targetability of folate receptor-mediated mitoxantrone albumin nanoparticles]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2006, Volume: 37, Issue:1 Topics: Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Drug Delivery Systems; Female; Folate Rec	2006
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. International journal of cancer, 2006, Jul-15, Volume: 119, Issue:2 Topics: Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; AT	2006
Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report. The Journal of reproductive medicine, 2007, Volume: 52, Issue:10 Topics: Adenocarcinoma; Antineoplastic Agents; Female; Heart Neoplasms; Humans; Middle Aged; Mitoxantrone; O	2007
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British journal of cancer, 2008, May-06, Volume: 98, Issue:9 Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S	2008
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. American journal of clinical oncology, 1984, Volume: 7, Issue:5 Topics: Anthraquinones; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Mitoxantrone; Ovarian Neop	1984
Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. American journal of clinical oncology, 1984, Volume: 7, Issue:6 Topics: Adult; Aged; Anthraquinones; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopen	1984
Disposition of mitoxantrone in patients. Cancer treatment reviews, 1983, Volume: 10 Suppl B Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Fe	1983
"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:3 Topics: Antineoplastic Agents; Catalysis; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Doxorubici	1995
Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:14 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Middle Aged; Mito	1994
Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. Oncology research, 1993, Volume: 5, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Damage; DNA, Neoplasm; DN	1993
Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer. Gynecologic oncology, 1994, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete	1994
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer research, 1993, Nov-01, Volume: 53, Issue:21 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carrier	1993
Circumvention of atypical multidrug resistance with tumor necrosis factor. Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:2 Topics: DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Drug Synergism; Etoposide; Fe	1994
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. European journal of gynaecological oncology, 1994, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chromatography, Hig	1994
Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone? European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:9 Topics: Female; Humans; Infusions, Parenteral; Mitoxantrone; Ovarian Neoplasms; Salvage Therapy	1993
Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease. Gynecologic oncology, 1993, Volume: 50, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Injections,	1993
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecologic oncology, 1993, Volume: 50, Issue:3 Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter	1993
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. Gynecologic oncology, 1993, Volume: 48, Issue:2 Topics: Dose-Response Relationship, Drug; Female; Humans; Injections, Intraperitoneal; Mitoxantrone; Ovarian	1993
[Current status and trends in chemotherapy of ovarian cancer]. Zhonghua fu chan ke za zhi, 1996, Volume: 31, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Mitoxantrone; Ovarian Neo	1996
Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 279, Issue:1 Topics: Antineoplastic Agents; Cisplatin; DNA Damage; Enzyme Inhibitors; Female; Humans; Mitoxantrone; Ovari	1996
Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine, 1996, Volume: 8, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Humans; Lethal Dose	1996
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease. European journal of gynaecological oncology, 1997, Volume: 18, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen	1997
Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53. Journal of immunotherapy (Hagerstown, Md. : 1997), 1999, Volume: 22, Issue:1 Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance,	1999
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer research, 1999, Sep-15, Volume: 59, Issue:18 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bind	1999
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. Archives of gynecology and obstetrics, 2000, Volume: 263, Issue:4 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant	2000
Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model. Cancer, 2000, Jul-15, Volume: 89, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Disease Models, Animal; Fema	2000
The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecologic oncology, 2001, Volume: 80, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi	2001
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily	2000
HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend? International journal of oncology, 2001, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Death; Cell Nucleus; DNA Primers; Female;	2001
Complications associated with intraperitoneal chemotherapy catheters. Gynecologic oncology, 2001, Volume: 81, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Catheters, I	2001
The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma. European journal of gynaecological oncology, 2001, Volume: 22, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,	2001
Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines. Japanese journal of cancer research : Gann, 1992, Volume: 83, Issue:7 Topics: Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Mitoxantrone; Ovarian Neoplasms; R	1992
Mitozantrone-induced onycholysis. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:1 Topics: Adenocarcinoma; Breast Neoplasms; Female; Humans; Male; Middle Aged; Mitoxantrone; Nail Diseases; Ov	1992
Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:6 Topics: Abdominal Neoplasms; Adult; Breast Neoplasms; Female; Humans; Injections, Intraperitoneal; Male; Mes	1992
[Local treatment of malignant pleural effusion in gynecologic tumors]. Zentralblatt fur Gynakologie, 1990, Volume: 112, Issue:9 Topics: Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mitoxantrone; Ovaria	1990
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:2 Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; H	1992
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. Zentralblatt fur Gynakologie, 1991, Volume: 113, Issue:23 Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon-	1991
[Results of intraperitoneal chemotherapy of ovarian cancer]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1991, Volume: 20, Issue:3 Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Cytarabine; Female; Humans; Infusions, Parenteral; Mi	1991
Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity. Gynecologic oncology, 1991, Volume: 41, Issue:1 Topics: Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans;	1991
Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:9 Topics: Animals; Antineoplastic Agents; Cell Line; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin	1990
[Local treatment of malignant pleural effusion in gynecologic tumors]. Zentralblatt fur Gynakologie, 1990, Volume: 112, Issue:12 Topics: Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mitoxantrone; Ovaria	1990
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:1 Topics: Carcinoma; Drug Evaluation; Female; Humans; Infusions, Parenteral; Mitoxantrone; Ovarian Neoplasms;	1990
First experiences with intraperitoneal chemotherapy in ovarian cancer. European journal of gynaecological oncology, 1990, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Infusions, Pa	1990
Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and gynecology, 1989, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality	1989
High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer research, 1989, Aug-15, Volume: 49, Issue:16 Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Humans; Male; Melpha	1989
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience). Acta medica Austriaca, 1989, Volume: 16, Issue:3-4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor	1989
A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:3 Topics: Adult; Aged; Cystadenocarcinoma; Drug Evaluation; Drug Tolerance; Female; Humans; Middle Aged; Mitox	1989
[Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies]. Geburtshilfe und Frauenheilkunde, 1988, Volume: 48, Issue:8 Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female	1988
Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer research, 1988, Oct-15, Volume: 48, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Drug Administration Schedu	1988
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. Onkologie, 1987, Volume: 10, Issue:1 Topics: Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Male; Mitoxantro	1987
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:7 Topics: Adult; Aged; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Mal	1988
Phase II study of mitoxantrone in epithelial ovarian cancer. Cancer treatment reports, 1987, Volume: 71, Issue:6 Topics: Adult; Drug Evaluation; Epithelium; Female; Humans; Middle Aged; Mitoxantrone; Ovarian Neoplasms	1987
Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:1 Topics: Cell Survival; Colony-Forming Units Assay; Doxorubicin; Drug Interactions; Female; Humans; Mitoxantr	1987
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Seminars in oncology, 1985, Volume: 12, Issue:3 Suppl 4 Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubici	1985
Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Investigational new drugs, 1985, Volume: 3, Issue:2 Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Chromatography, High Pr	1985

mitoxantrone and Cancer of Ovary

Research Excerpts

Research

Studies (96)

Authors

Clinical Trials (3)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Perry, PJ	1
Gowan, SM	1
Reszka, AP	1
Polucci, P	1
Jenkins, TC	1
Kelland, LR	1
Neidle, S	1
Garg, AD	1
Elsen, S	1
Krysko, DV	1
Vandenabeele, P	1
de Witte, P	1
Agostinis, P	1
Vera, CA	1
Oróstica, L	1
Gabler, F	1
Ferreira, A	1
Selman, A	1
Vega, M	1
Romero, CA	1
Kehoe, SM	1
Williams, NL	1
Yakubu, R	1
Levine, DA	1
Chi, DS	2
Sabbatini, PJ	1
Aghajanian, CA	1
Barakat, RR	3
Abu-Rustum, NR	1
Brimacombe, KR	1
Hall, MD	1
Auld, DS	1
Inglese, J	1
Austin, CP	1
Gottesman, MM	1
Fung, KL	1
Zhang, LK	2
Hou, SX	2
Zhang, JQ	1
Hu, WJ	1
Wang, CY	1
Hawes, D	1
Liu, PY	3
Muggia, FM	2
Wilczynski, S	1
Cote, R	1
Felix, J	1
Terada, K	1
Belt, RJ	1
Alberts, DS	9
Stiff, PJ	2
Shpall, EJ	1
Wilczynski, SP	1
Callander, NS	1
Scudder, SA	1
Jazieh, AR	1
Samlowski, W	1
McCoy, J	1
Perry, WL	1
Shepard, RL	1
Sampath, J	1
Yaden, B	1
Chin, WW	1
Iversen, PW	1
Jin, S	1
Lesoon, A	1
O'Brien, KA	1
Peek, VL	1
Rolfe, M	1
Shyjan, A	1
Tighe, M	1
Williamson, M	1
Krishnan, V	1
Moore, RE	1
Dantzig, AH	1
Mao, SJ	1
Wei, DP	1
Song, XR	1
Jekerle, V	1
Klinkhammer, W	1
Scollard, DA	1
Breitbach, K	1
Reilly, RM	1
Piquette-Miller, M	1
Wiese, M	1
Micha, JP	1
Goldstein, BH	1
Zusman, D	1
Rettenmaier, MA	1
Epstein, HD	1
Brown, JV	1
Calcagno, AM	1
Fostel, JM	1
To, KK	1
Salcido, CD	1
Martin, SE	1
Chewning, KJ	1
Wu, CP	1
Varticovski, L	1
Bates, SE	1
Caplen, NJ	1
Ambudkar, SV	1
Tada, A	1
Ogawa, M	1
Usui, N	1
Inagaki, J	1
Horikoshi, N	1
Inoue, K	1
Ikeda, K	1
Adachi, K	1
Nakada, H	1
Okada, Y	1
Hilgers, RD	1
Rivkin, SE	1
Von Hoff, DD	1
Muss, HB	1
Asbury, R	1
Bundy, B	1
Ehrlich, CE	1
Graham, J	1
Peng, YM	3
Leigh, S	1
Davis, TP	1
Woodward, DL	1
Di Leo, A	3
Bajetta, E	4
Nolè, F	1
Biganzoli, L	4
Ferrari, L	1
Oriana, S	4
Riboldi, G	3
Bohm, S	4
Spatti, G	3
Raspagliesi, F	1
Cimoli, G	6
Valenti, M	4
Noviello, E	3
Parodi, S	8
Mazzoni, A	2
Rovini, E	1
De Sessa, F	3
Russo, P	7
Khalil, A	1
Ciobanu, N	1
Sparano, JA	1
Gucalp, R	1
Dutcher, JP	1
Wiernik, PH	1
Stiff, P	1
Bayer, R	1
Camarda, M	1
Tan, S	1
Dolan, J	1
Potkul, R	1
Loutfi, S	1
Kinch, L	1
Sosman, J	1
Peace, D	1
Lupi, G	2
Zunino, F	1
Di Re, F	2
Nicoletto, MO	4
Padrini, R	3
Koussis, H	1
Rosabian, A	1
Aversa, S	1
Endrizzi, L	2
Azzoni, P	2
Palumbo, M	3
Fiorentino, MV	1
Leo, AD	1
Vicario, G	1
Conte, P	2
Malmström, H	1
Carstensen, J	1
Simonsen, E	1
Oza, AM	1
ten Bokkel Huinink, W	1
Dubbelman, R	2
Soepenberg, O	1
Mandjes, I	1
Aartsen, E	1
McVie, JG	2
Mäenpää, J	1
Kivinen, S	1
Räisänen, I	1
Sipilä, P	1
Väyrynen, M	1
Gröhn, P	1
Hamaguchi, K	1
Godwin, AK	1
Yakushiji, M	1
O'Dwyer, PJ	1
Ozols, RF	1
Hamilton, TC	1
Dufour, P	2
Bergerat, JP	2
Barats, JC	2
Giron, C	1
Duclos, B	1
Dellenbach, P	2
Ritter, J	1
Renaud, R	2
Audhuy, B	2
Oberling, F	1
Lorusso, V	1
Catino, A	1
Gargano, G	1
Fioretto, A	1
Berardi, F	1
de Lena, M	1
McKenzie, RS	1
Sosman, JA	1
Dolan, JR	1
Rad, N	1
McCloskey, T	2
Markman, M	9
Ferrazzi, E	3
Nascimben, O	1
Visonà, E	2
Tumolo, S	2
Costa, L	1
Vinante, O	1
Monfardini, S	2
Frasci, G	1
Tortoriello, A	1
Facchini, G	1
Conforti, S	1
Cardone, A	1
Persico, G	1
Mastrantonio, P	1
Iaffaioli, RV	1
Tarraza, HM	2
Boyce, CR	1
Smith, WG	1
Jones, MA	1
Alberts, D	1
Rubin, S	6
Hakes, T	6
Lewis, JL	6
Reichman, B	6
Jones, W	6
Curtin, J	4
Barakat, R	5
Brodar, F	1
Almadrones, L	5
Hoskins, W	6
Wallace, DL	1
O'Toole, RV	1
Terada, KY	1
Franklin, EW	1
Herrer, GW	1
Goldberg, DA	1
Hannigan, EV	1
Nardi, M	1
Della Giulia, M	1
Pollera, CF	1
Marolla, P	1
Ruggeri, EM	1
Iacovelli, A	1
Atlante, G	1
Calabresi, F	1
Mariani, L	1
Mènard, S	1
Pilotti, S	1
Fabbiani, M	1
Gebbia, V	1
Lian, L	1
Marzola, M	1
Parma, G	1
Bonazzi, C	1
Colombo, N	1
Maneo, A	1
Pittelli, MR	1
Mangioni, C	1
Debernardis, D	1
Stanzione, S	1
Ottoboni, C	2
Clerico, L	1
Mancuso, T	1
Topuz, E	4
Aydiner, A	3
Saip, P	4
Bengisu, E	4
Berkman, S	4
Disci, R	1
Cosimi, A	1
Allievi, E	1
Galletti, P	1
Fennelly, D	2
Pizzuto, F	1
Venkatraman, ES	1
Brown, C	1
Curtin, JP	2
Weaver, CH	1
Greco, FA	1
Hainsworth, JD	1
Zhen, B	1
Baldwin, P	1
Wittlin, F	1
Lewis, M	1
West, WH	1
Schwartzberg, L	1
Buckner, CD	1
Aydmer, A	1
Salihoğlu, Y	3
Lichtman, SM	1
Homesley, H	1
Kennedy, A	1
Webster, K	1
Ernst, S	1
Omura, G	1
Belinson, J	1
Kurbacher, CM	1
Bruckner, HW	1
Cree, IA	1
Kurbacher, JA	1
Wilhelm, L	1
Pöch, G	1
Indefrei, D	1
Mallmann, P	2
Andreotti, PE	1
Norum, J	1
Lunde, P	1
Aasebø, U	1
Himmelmann, A	1
Sleijfer, S	1
Le, TK	1
de Jong, S	1
Timmer-Bosscha, H	1
Withoff, S	1
Mulder, NH	2
Husain, A	2
Sabbatini, P	2
Spriggs, D	1
Aghajanian, C	1
Venkatraman, E	1
Tasinato, R	1
Godina, M	1
Biral, M	1
Nicoletto, O	1
Griggio, L	1
Maliepaard, M	2
van Gastelen, MA	1
de Jong, LA	1
Pluim, D	1
van Waardenburg, RC	1
Ruevekamp-Helmers, MC	1
Floot, BG	1
Schellens, JH	2
Yokoyama, Y	1
Futagami, M	1
Fukushi, Y	1
Sakamoto, T	1
Higuchi, T	1
Fujii, S	1
Sato, S	1
Takami, H	1
Saito, Y	1
Galeotti, F	1
Cartei, G	1
Riddi, F	1
De Paoli, M	1
Corsini, A	1
Volz, J	1
Volz-Köster, S	1
Kanis, S	1
Klee, D	1
Ahlert, C	1
Melchert, F	1
Tas, F	2
Sozen, T	1
Prasad, M	1
Abu-Rustum, N	1
Brown, CL	1
Poynor, EA	1
Hoskins, WJ	1
Artioli, G	1
Donach, M	1
Sileni, VC	1
Talamini, R	1
Veronesi, A	1
Amichetti, M	1
Salvagno, L	1
Prosperi, A	1
Scheper, RJ	1
Scheffer, GL	1
Jonker, JW	1
Smit, JW	1
Beijnen, JH	1
Schinkel, AH	1
Makhija, S	1
Leitao, M	1
Bellin, N	1
Leon, L	1
Spriggs, DR	1
Eralp, Y	1
Saliho, Y	1
Tournigand, C	1
Louvet, C	2
Molitor, JL	1
Dehni, N	1
Lejeune, V	1
Sezeur, A	1
Pigne, A	2
Marpeau, L	2
Cady, J	2
de Gramont, A	2
Billi, G	2
Oliva, C	1
Venturini, M	1
Mitchell, PL	1
Harvey, VJ	1
Nagel, JD	1
Varossieau, FJ	1
ten Bokkel Huinink, WW	1
Seitzer, D	2
Musch, E	3
Kuhn, W	2
Werner, A	2
Chronides, A	1
Diedrich, K	2
Wagner, U	1
Krebs, D	2
Carroll, R	1
De Cain, M	1
Jones, M	1
Demuynck, B	1
Varette, C	1
Gonzalez-Canali, G	1
Herbulot, P	1
Lagadec, B	1
Hendrick, AM	1
Harris, AL	1
Cantwell, BM	1
Vigani, A	1
Chiara, S	1
Miglietta, L	1
Repetto, L	1
Conte, PF	1
Morelli, L	1
Maloisel, F	1
Ritter, P	1
Herbrecht, R	1
Wendling, C	1
Boven, E	1
Schlüper, HM	1
Erkelens, CA	1
Pinedo, HM	1
George, M	1
Gitsch, E	1
Sevelda, P	1
Schmidl, S	1
Salzer, H	3
Lawton, FG	1
Redman, CW	1
Luesley, DM	1
Chan, KK	1
Blackledge, G	2
Mulder, PO	1
Sleijfer, DT	1
Willemse, PH	1
de Vries, EG	1
Uges, DR	1
Coleman, R	1
Clarke, J	1
Gore, M	1
Wiltshaw, E	1
Slevin, M	1
Harper, P	1
Bode, U	1
Surwit, EA	1
Rivest, R	1
Graham, V	1
McDonald, L	1
Roe, D	1
Blöchl-Daum, B	2
Eichler, HG	2
Rainer, H	2
Jakesz, R	2
Steger, G	2
Schüller, J	2
Günther, E	2
Proksch, P	1
Ehninger, G	2
Proksch, B	1
Lawton, F	1
Mould, J	1
Latief, T	1
Watson, R	1
Chetiyawardana, AD	1
Gibby, EM	1
Boyse, O	1
Hill, BT	1
Young, L	1
Mason, N	1
Salmon, SE	1
Bowden, GT	1
Dalton, WS	1
Mackel, C	1